DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Business Wire
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease (CKD). This study is designed to investigate the safety, tolerability and efficacy of DM199 for the treatment of CKD in African Americans with hypertension and CKD in individuals with IgA Nephropathy.“We are thrilled to announce dosing of the first patient in our Phase II CKD study, a significant milestone in the development of DM199,” said Dr. Harry Alcorn, Chief Medical Officer of DiaMedica Therapeutics. “We believe that DM199 protein replacement therapy could have a meaningful impact on the lives of patients with chronic kidney disease.”About the REDUX Phase II Trial of DM199 for Chronic Kidney DiseaseThe Phase II REDUX clinical trial is a multi-center, open-label investigation of 60 participants with Stage II or III CKD, who will be enrolled
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- DiaMedica Therapeutics GAAP EPS of -$0.15 in-line [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial ResultsBusiness Wire
DMAC
Earnings
- 11/13/24 - Miss
DMAC
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- DMAC's page on the SEC website